(Updated - March 15, 2024 8:26 AM EDT)

JMP Securities analyst Jonathan Wolleben raised the price target on Madrigal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'March 19, 2024 2:50 PM Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)March 18, 2024 4:04 PM Madrigal Pharmaceuticals (MDGL) PT Raised to $400 at Jefferies, 'label hit our bull case'March 15, 2024 7:51 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $375 at OppenheimerMarch 15, 2024 7:37 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $390 at TD CowenMarch 15, 2024 6:54 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $377 at Canaccord GenuityMarch 15, 2024 6:49 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'March 15, 2024 6:11 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $389 at CitiMarch 15, 2024 3:49 AM Madrigal Pharma (MDGL) option IV into FDA approves Madrigal Pharmaceuticals' RezdiffraMarch 15, 2024 3:48 AM B.Riley Upgrades Madrigal Pharmaceuticals (MDGL) to NeutralMarch 15, 2024 3:10 AM After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gainMarch 14, 2024 4:48 PM Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisMarch 14, 2024 4:16 PM Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver FibrosiMarch 14, 2024 4:15 PM Madrigal Pharma (MDGL) option implied volatility into FDA approvalMarch 14, 2024 3:51 PM Madrigal Pharma (MDGL): FDA Approves rezdiffraMarch 14, 2024 3:45 PM Madrigal Gets FDA Approval For NDA For RezdiffraMarch 14, 2024 3:45 PM Madrigal Pharma (MDGL) Halted, News PendingMarch 14, 2024 3:30 PM